Appendix to the Consolidated Financial Summary FY2023 Second-Half
May 10th, 2024
JCR Pharmaceuticals Co., Ltd.
[Securities code]4552, Prime. TSE
Note : This document has been translated from a part of the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.
Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Contents
2 | |
3 | |
4 | |
5 | |
6 | |
7 | |
<Reference> | |
8 | |
9 | |
Trends in Sales Breakdown - Consolidated | 10 |
Net Sales Trends (Excluding AZD1222 Stock Solution) | 11 |
Trends in Composition Ratio of Cost/Expense | 12 |
Correlation between R&D Expenses (before Deducting) and Main R&D Pipeline | 13 |
Net Sales Trends by Product FY2024 Forecast | 14 |
Net Sales Trends (Excluding AZD1222 Stock Solution) FY2024 Forecast | 15 |
IZCARGO® Prescription Status | 16 |
GROWJECT® Market Trends | 17 |
GROWJECT® Market Trends | 18 |
Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved. | 1 |
Consolidated Financial Results | (Unit: million yen) | ||||||
FY2022 | FY2023 | ||||||
Consolidated | |||||||
Year-on-year | Full-year | Progress | |||||
results | results | Difference | Ratio | forecast | rate | ||
(Revised) | |||||||
◆ Operating income 7,531 million yen
Year-on-year: +2,556 million yen
Net sales | 34,343 | 42,871 | +8,528 | +24.8% | 45,400 | 94.4% |
Cost of sales | 8,886 | 11,620 | +2,733 | +30.8% | 12,400 | 93.7% |
Gross profit | 25,456 | 31,251 | +5,794 | +22.8% | 33,000 | 94.7% |
Selling, general and | 20,480 | 23,719 | +3,238 | +15.8% | 22,500 | 105.4% |
administrative expenses | ||||||
SG&A | 11,678 | 12,484 | +806 | +6.9% | 12,800 | 97.5% |
R&D expenses | 8,802 | 11,234 | +2,431 | +27.6% | 9,700 | 115.8% |
Operating profit | 4,975 | 7,531 | +2,556 | +51.4% | 10,500 | 71.7% |
Non-operating income | 541 | 1,056 | +515 | +95.2% | ー | ー |
Non-operating expenses | 99 | 1,324 | +1,225 | + 1236.6% | ー | ー |
Ordinary profit | 5,418 | 7,264 | +1,846 | +34.1% | 10,000 | 72.6% |
Extraordinary income | 10 | 0 | (9) | (94.0)% | ー | ー |
Extraordinary losses | 16 | 20 | +4 | +26.3% | ー | ー |
Profit before income taxes | 5,412 | 7,244 | +1,831 | +33.8% | ー | ー |
FY2022
Net sales Cost of sales
SG&A
R&D expenses
FY2023
4,975
+ 8,528
△ 2,733
△ 806
- 2,431
7,531
(Unit: million yen)
Income taxes | 1,625 | 1,707 | +82 | +5.1% | ー | ー |
Profit attributable to owners of | 3,772 | 5,507 | +1,735 | +46.0% | 7,300 | 75.4% |
parent | ||||||
(Reference) R&D expenses before | 9,480 | 12,787 | 3,307 | +34.9% | 11,700 | 109.3% |
deducting contribution amount by | ||||||
collaborative R&D destinations | ||||||
Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Net sales | FY2022 | FY2023 | YoY Ratio |
Cost of sales ratio | 25.9% | 27.1% | +1.2% |
Cost of sales ratio | 32.0% | 32.8% | +0.8% |
*Excluding Income from | |||
contractual payment | |||
R&D expense ratio | 25.6% | 26.2% | +0.6% |
Operating profit ratio | 14.5% | 17.6% | +3.1% |
2
Breakdown of Net Sales - Consolidated | (Unit: million yen) | ||||
FY2022 | FY2023 | ||||
Year-on-year | Full year | Progress | |||
results | results | forecast | |||
rate | |||||
Difference Ratio | (Revised) | ||||
◆Net sales 42,871 million yen
Year-on-year;+8,528 million
GROWJECT® | 12,261 | 17,913 | +5,652 | +46.1% | 19,500 | 91.9% |
IZCARGO®* | 4,414 | 5,171 | +757 | +17.2% | 5,200 | 99.4% |
TEMCELL®HS Inj. | 3,404 | 3,236 | (168) | (4.9)% | 3,300 | 98.1% |
Treatments for renal | 4,696 | 4,652 | (44) | (0.9)% | 5,000 | 93.0% |
anemia | ||||||
Epoetin Alfa BS Inj. | 2,710 | 1,994 | (716) | (26.4)% | 2,200 | 90.6% |
[JCR] | ||||||
Darbepoetin Alfa BS Inj. | 1,986 | 2,658 | +672 | +33.8% | 2,800 | 94.9% |
[JCR] | ||||||
Agalsidase Beta BS I.V. | 964 | 1,661 | +697 | +72.2% | 1,400 | 118.6% |
Infusion [JCR] | ||||||
Total Core Products | 25,741 | 32,636 | +6,895 | +26.8% | 34,400 | 94.9% |
Income from contractual | 6,546 | 7,413 | +867 | +13.3% | 8,100 | 91.5% |
payment | ||||||
Other* | 123 | 2,820 | +2,697 | +2192.7% | 2,900 | 97.2% |
AZD1222 stock solution | 1,931 | ー | (1,931) | (100.0)% | ー | ー |
FY2022
GROWJECT®
IZCARGO®
TEMCELL®
Epoetin Alfa
Darbepoetin Alfa
Agalsidase Beta
Income from contractual payment
Other
AZD1222
FY2023
34,343
- 5,652
-
757
(168)
-
757
(716)
+672
+697
+ 867
+ 2,697
(1,931)
42,871
Total Net Sales | 34,343 | 42,871 | +8,528 | +24.8% | 45,400 | 94.4% |
(Unit: million yen)
Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved. | * Sales of IZCARGO® related to NPS is included in Other | 3 |
On 13 May 2024, the Progress rate for Total Net Sales was corrected. Correction is indicated by underlining. |
Financial Status - Consolidated
(Unit: million yen)
End-Mar. | End-Mar. | Change | |||
2023 | 2024 | ・Main | |||
Increase/decrease | |||||
Total | +9,779 | ||||
• | Cash and deposits | ||||
+5,477 | |||||
Current | 47,802 | 57,581 | • | Accounts receivable - | |
assets | trade, and contract | ||||
assets | |||||
+3,797 | |||||
• | Inventories | ||||
+2,419 | |||||
Total | (2,490) | ||||
Non- | • | Property, plant and | |||
current | 47,135 | 44,644 | |||
assets | equipment | ||||
(2,640) | |||||
Total | 94,937 | 102,226 | +7,288 | ||
Current liabilities
Non- current liabilities
Total liabilities
Total net assets
Total
End-Mar. | End-Mar. | Change | |||
2023 | 2024 | ・Main | |||
Increase/decrease | |||||
Total | (5,626) | ||||
• | Income taxes | ||||
35,762 | 30,135 | payable | +1,623 | ||
• | Short-term | ||||
borrowings | |||||
(7,850) | |||||
Total | +8,853 | ||||
6,761 | 15,615 | • | Long-term | +8,850 | |
borrowings | |||||
42,523 | 45,750 | Total | +3,226 | ||
52,413 | 56,475 | Total | +4,061 | ||
94,937 | 102,226 | +7,288 | |||
Equity ratio
54.2%
54.2%
Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.
On 13 May 2024, the change in total liabilities was corrected. Correction is indicated by underlining. | 4 |
Cash Flows - Consolidated
Operating Activities
Investing Activities
Financing Activities
Cash and Cash Equivalents at
End of Period
18,756
13,278
9,312
1,948
(2,690) (2,031)
(5,500)
(15,002)
FY2022FY2023
Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.
(Unit: million yen) | FY2022 | FY2023 | Year-on-year | |
Profit before income taxes | 5,412 | 7,244 | +1,831 | |
Depreciation | 1,997 | 3,197 | +1,199 | |
Decrease (increase) in trade receivables and | 3,269 | (3,390) | (6,659) | |
accounts receivable - other | ||||
Decrease (increase) in inventories | (3,877) | (2,437) | +1,439 | |
Increase (decrease) in trade payables and | (2,162) | (281) | +1,880 | |
accounts payable - other | ||||
Income taxes paid | (8,279) | 1,982 | +10,261 | |
Other | (1,859) | 2.998 | +4,857 | |
Operating Activities | (5,500) | 9,312 | 14,813 | |
Capital investment(property,plant and equipment) | (8,560) | (2,096) | +6,463 | |
Purchase of shares of subsidiaries and associates | (6,717) | (600) | +6,117 | |
Other | 275 | 5 | (269) | |
Investing Activities | (15,002) | (2,690) | +12,312 | |
Bollowings | 4,700 | 500 | (4,200) | |
Dividends paid/ treasury shares | (2,729) | (2,485) | +244 | |
Other | (22) | (46) | (24) | |
Financing Activities | 1,948 | (2,031) | (3,980) | |
Net increase (decrease) in cash and cash | (17,454) | 5,477 | +22,932 | |
equivalents | ||||
Cash and Cash Equivalents at End of Period | 13,278 | 18,756 | +5,477 | |
FY2022 | FY2023 | |||
Depreciation | 1,997 | 3,197 | ||
Capital investment (after subsidy deduction) | 4,330 | 2,096 | 5 |
Consolidated Financial Results FY2024 forecast
(Unit: million yen)
FY2023 | FY2024(forecast) | ||||
Consolidated | |||||
results | forecast | Year-on-year | |||
Difference | Ratio | ||||
Net sales | 42,871 | 41,300 | (1,571) | (3.7)% | |
Cost of sales | 11,620 | 10,400 | (1,220) | (10.5)% | |
Gross profit | 31,251 | 30,900 | (351) | (1.1)% | |
Selling, general and | 23,719 | 25,500 | +1,781 | +7.5% | |
administrative expenses | |||||
SG&A | 12,484 | 12,500 | +16 | + 0.1% | |
R&D expenses | 11,234 | 13,000 | +1,766 | + 15.7% | |
Operating profit | 7,531 | 5,400 | (2,131) | (28.3)% | |
Ordinary profit | 7,264 | 4,600 | (2,664) | (36.7)% | |
Profit attributable to owners of | 5,507 | 3,700 | (1,807) | (32.8)% | |
parent | |||||
(Reference) R&D expenses | |||||
before deducting contribution | 12,787 | 15,062 | +2,275 | +17.8% | |
amount by collaborative R&D | |||||
destinations |
Net sales | FY2023 | FY2024 | YoY |
(forecast) | Ratio | ||
Cost of sales ratio | 27.1% | 25.2% | (1.9)% |
Cost of sales ratio | 32.8% | 31.3% | (1.4)% |
*Excluding Income from | |||
contractual payment | |||
R&D expense ratio | 26.2% | 31.5% | +5.3% |
Operating profit ratio | 17.6% | 13.1% | (4.5)% |
On 13 May 2024, the year-on-year ratio changes in the cost of sales, gross profit, operating profit, ordinary profit and profit attributable to owners of parent/Profit were corrected. Corrections are indicated by underlining.
Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved. | 6 |
Breakdown of Net Sales - Consolidated | FY2024 forecast | (Unit: million yen) | |||||||
FY2023 | FY2024(forecast) | ||||||||
results | forecast | Year-on-year | |||||||
Difference | Ratio | ||||||||
GROWJECT® | 17,913 | 18,300 | +387 | +2.2% | |||||
IZCARGO®* | 5,171 | 5,700 | +529 | +10.2% | |||||
TEMCELL®HS Inj. | 3,236 | 2,800 | (436) | (13.5)% | |||||
4,200 | |||||||||
Treatments for renal anemia | 4,652 | (452) | (9.7)% | ||||||
Epoetin Alfa BS Inj. [JCR] | 1,994 | 2,200 | +206 | +10.3% | |||||
Darbepoetin Alfa BS Inj. [JCR] | 2,658 | 2,000 | (658) | (24.8)% | |||||
Agalsidase Beta BS I.V. | 1,661 | 1,100 | (561) | (33.8)% | |||||
Infusion [JCR] | |||||||||
Total Core Products | 32,636 | 32,100 | (536) | (1.6)% | |||||
Income from contractual | 7,413 | 8,100 | +687 | +9.3% | |||||
payment | |||||||||
Other* | 2,820 | 1,100 | (1,720) | (61.0)% | |||||
Total Net Sales | 42,871 | 41,300 | (1,571) | (3.7)% | |||||
Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved. | * Sales of IZCARGO® related to NPS is included in Other | 7 | |||||||
On 13 May 2024, some of the FY2024 forecast, year-on-year difference, and ratio were corrected. Corrections are indicated by underlining. |
Net Sales Trends by Product
Recombinant human growth hormone product | 17,913 | ||
GROWJECT® | |||
13,256 | 12,945 | 12,261 | |
NHI | NHI | ||
price | price | ||
NHI price | revision | revision | |
revision | (8.1)% | (5.3)% | |
FY2020 | FY2021 | FY2022 | FY2023 |
(Unit: million yen)
Recombinant therapeutic enzyme for mucopolysaccharidosis II (MPS II)
IZCARGO® I.V. infusion 10mg
From April 24, 2023: Co-promotion with Sumitomo Pharma Co., Ltd.
4,414 | 5,171 | |
3,003 | ||
FY2021 | FY2022 | FY2023 |
*Excluding sales of IZCARGO® related to NPS
Human somatic stem cell-processed products
Human (allogenic) bone marrow-derived mesenchymal stem cells
TEMCELL® HS Inj.
3,497 | 3,404 | 3,236 | |
2,441 | |||
FY2020 | FY2021 | FY2022 | FY2023 |
Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.
Recombinant erythropoietin product
Epoetin Alfa BS Inj. [JCR]
Long-actingerythropoiesis-stimulating agent
Darbepoetin Alfa BS Inj. [JCR]
Epoetin Alfa
Darbepoetin Alfa
3,809
2,998
1,986 | 2,658 | |||||||
NHI price | NHI price | |||||||
3,278 NHI price | Epo (7.0)% | Epo (2.6)% | ||||||
2,876 | revision | 2,710 | revision | 1,994 | ||||
revision | Darbe (12.3)% | Darbe (12.2)% | ||||||
FY2020 | FY2021 | FY2022 | FY2023 | |||||
Recombinant treatment for Fabry disease
Agalsidase Beta BS I.V. Infusion [JCR]
Apr. 2022: Sales transferred to Sumitomo Pharma
1,661 | |||
964 | |||
711 | |||
470 | NHI price | NHI price | |
NHI price | revision | revision | |
revision | (5.2)% | (4.4)% | |
FY2020 | FY2021 | FY2022 | FY2023 |
8 |
Composition of Net Sales by Item
6%
17%
Total net sales | 42% |
4% | 42,871 |
million yen
6%
5%12%
8%
FY2023
● GROWJECT®
17,913 million yen
● IZCARGO®
5,171 million yen
● TEMCELL®HS Inj.
3,236 million yen
● Epoetin Alfa BS Inj. [JCR]
1,994 million yen
● Darbepoetin Alfa BS Inj. [JCR] 2,658 million yen
● Agalsidase Beta BS I.V. Infusion [JCR]
1,661 million yen
● Income from contractual payment | 7,413 million yen |
● Other | 2,820 million yen |
*Excluding sales of IZCARGO® related to NPS
Copyright © 2024 JCR Pharmaceuticals Co., Ltd. All rights reserved.
On 13 May 2024, the sales composition percentage for 'Other' was corrected. Correction is indicated by underlining. | 9 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
JCR Pharmaceuticals Co. Ltd. published this content on 13 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 May 2024 13:42:24 UTC.